Baseline characteristics of 16 patients treated with 19-28z CAR EBV-VSTs
| Characteristic . | Cohort 1, n = 8 . | Cohort 2, n = 6 . | Cohort 3, n = 2 . | Overall, N = 16 . |
|---|---|---|---|---|
| Disease, n (%) | ||||
| B-ALL | 6 (75) | 0 (0) | 0 (0) | 6 (38) |
| NHL | 2 (25) | 6 (100) | 2 (100) | 10 (62) |
| Burkitt lymphoma | 1 | 0 | 0 | 1 (6) |
| DLBCL | 0 | 3 | 1 (50) | 4 (25) |
| PMBCL | 0 | 2 | 0 | 2 (12) |
| Marginal zone lymphoma | 0 | 1 | 0 | 1 (6) |
| SLL/CLL --> DLBCL | 0 | 0 | 1 (50) | 1 (6) |
| CLL | 1 | 0 | 0 | 1 (6) |
| Age at treatment (day 0), median (range), y | 13 (1-68) | 62 (17-71) | 49 (48-51) | 30 (1-71) |
| Median prior lines therapy, median (range) | 5 (4-11) | 3.5 (3-6) | 10; 10 | 5 (3-11) |
| Cell dose, n (%) | ||||
| 1 × 106 T cells per kg | 5 (62) | 0 (0) | 0 (0) | 5 (31) |
| 3 × 106 T cells per kg | 2 (25) | 6 (100) | 2 (100) | 10 (62) |
| 1 × 107 T cells per kg | 1 (12) | 0 (0) | 0 (0) | 1 (6) |
| Number of cycles, n (%) | ||||
| 1 | 3 (38) | 1 (17) | 0 (0) | 4 (25) |
| 2 | 3 (38) | 1 (17) | 0 (0) | 4 (25) |
| 3 | 2 (25) | 4 (67) | 2 (100) | 8 (50) |
| CAR EBV donor, n (%) | ||||
| Third party | 4 (50) | 6 (100) | 2 (100) | 12 (75) |
| HCT donor (sibling) | 2 (25) | 0 (0) | 0 (0) | 2 (12) |
| HCT donor (URD) | 2 (25) | 0 (0) | 0 (0) | 2 (12) |
| HLA matching, n (%) | ||||
| 10/10 | 3 (38) | 0 (0) | 0 (0) | 3 (19) |
| 6/10 | 1 (12) | 1 (17) | 0 (0) | 2 (12) |
| 5/10 | 0 (0) | 1 (17) | 0 (0) | 1 (6) |
| 4/10 | 2 (25) | 1 (17) | 0 (0) | 3 (19) |
| 2/10 | 2 (25) | 3 (50) | 2 (100) | 7 (44) |
| HCT to CAR EBV-VST, median (range), d | 393.5 (99-1128) | 21 (14-60) | 34; 89 | 94 (14-1128) |
| Characteristic . | Cohort 1, n = 8 . | Cohort 2, n = 6 . | Cohort 3, n = 2 . | Overall, N = 16 . |
|---|---|---|---|---|
| Disease, n (%) | ||||
| B-ALL | 6 (75) | 0 (0) | 0 (0) | 6 (38) |
| NHL | 2 (25) | 6 (100) | 2 (100) | 10 (62) |
| Burkitt lymphoma | 1 | 0 | 0 | 1 (6) |
| DLBCL | 0 | 3 | 1 (50) | 4 (25) |
| PMBCL | 0 | 2 | 0 | 2 (12) |
| Marginal zone lymphoma | 0 | 1 | 0 | 1 (6) |
| SLL/CLL --> DLBCL | 0 | 0 | 1 (50) | 1 (6) |
| CLL | 1 | 0 | 0 | 1 (6) |
| Age at treatment (day 0), median (range), y | 13 (1-68) | 62 (17-71) | 49 (48-51) | 30 (1-71) |
| Median prior lines therapy, median (range) | 5 (4-11) | 3.5 (3-6) | 10; 10 | 5 (3-11) |
| Cell dose, n (%) | ||||
| 1 × 106 T cells per kg | 5 (62) | 0 (0) | 0 (0) | 5 (31) |
| 3 × 106 T cells per kg | 2 (25) | 6 (100) | 2 (100) | 10 (62) |
| 1 × 107 T cells per kg | 1 (12) | 0 (0) | 0 (0) | 1 (6) |
| Number of cycles, n (%) | ||||
| 1 | 3 (38) | 1 (17) | 0 (0) | 4 (25) |
| 2 | 3 (38) | 1 (17) | 0 (0) | 4 (25) |
| 3 | 2 (25) | 4 (67) | 2 (100) | 8 (50) |
| CAR EBV donor, n (%) | ||||
| Third party | 4 (50) | 6 (100) | 2 (100) | 12 (75) |
| HCT donor (sibling) | 2 (25) | 0 (0) | 0 (0) | 2 (12) |
| HCT donor (URD) | 2 (25) | 0 (0) | 0 (0) | 2 (12) |
| HLA matching, n (%) | ||||
| 10/10 | 3 (38) | 0 (0) | 0 (0) | 3 (19) |
| 6/10 | 1 (12) | 1 (17) | 0 (0) | 2 (12) |
| 5/10 | 0 (0) | 1 (17) | 0 (0) | 1 (6) |
| 4/10 | 2 (25) | 1 (17) | 0 (0) | 3 (19) |
| 2/10 | 2 (25) | 3 (50) | 2 (100) | 7 (44) |
| HCT to CAR EBV-VST, median (range), d | 393.5 (99-1128) | 21 (14-60) | 34; 89 | 94 (14-1128) |
-->, initial to subsequent diagnosis; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; SLL, small lymphocytic lymphoma; URD, unrelated donor.